Developing a Decision Aid for Clinical Obesity Services in the Real World: the DACOS Nationwide Pilot Study
- PMID: 38467898
- PMCID: PMC11127827
- DOI: 10.1007/s11695-024-07123-6
Developing a Decision Aid for Clinical Obesity Services in the Real World: the DACOS Nationwide Pilot Study
Abstract
Purpose: The purpose of this study is to develop a decision aid tool using "real-world" data within the Australian health system to predict weight loss after bariatric surgery and non-surgical care.
Materials and methods: We analyzed patient record data (aged 16+years) from initial review between 2015 and 2020 with 6-month (n=219) and 9-/12-month (n=153) follow-ups at eight clinical obesity services. Primary outcome was percentage total weight loss (%TWL) at 6 months and 9/12 months. Predictors were selected by statistical evidence (p<0.20), effect size (±2%), and clinical judgment. Multiple linear regression and bariatric surgery were used to create simple predictive models. Accuracy was measured using percentage of predictions within 5% of the observed value, and sensitivity and specificity for predicting target weight loss of 5% (non-surgical care) and 15% (bariatric surgery).
Results: Observed %TWL with bariatric surgery vs. non-surgical care was 19% vs. 5% at 6 months and 22% vs. 5% at 9/12 months. Predictors at 6 months with intercept (non-surgical care) of 6% include bariatric surgery (+11%), BMI>60 (-3%), depression (-2%), anxiety (-2%), and eating disorder (-2%). Accuracy, sensitivity, and specificity were 58%, 69%, and 56%. Predictors at 9/12 months with intercept of 5% include bariatric surgery (+15%), type 2 diabetes (+5%), eating disorder (+4%), fatty liver (+2%), atrial fibrillation (-4%), osteoarthritis (-3%), sleep/mental disorders (-2-3%), and ≥10 alcohol drinks/week (-2%). Accuracy, sensitivity, and specificity were 55%, 86%, and 53%.
Conclusion: Clinicians may use DACOS to discuss potential weight loss predictors with patients after surgery or non-surgical care.
Keywords: Decision support model; Management; Obesity; Weight loss.
© 2024. The Author(s).
Conflict of interest statement
This pilot work was supported by grants from Novo Nordisk Pharmaceuticals, in partnership with the National Association of Clinical Obesity Services (NACOS) and Western Sydney University (P00026163). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the abstract. EA is the Founding President of NACOS and is employed at Western Sydney University. He has also received honoraria from Novo Nordisk and NACOS for participating at conferences. KW has received honoraria from Novo Nordisk, Eli Lilly, Pfizer, and Boehringer Ingelheim. TG has received honoraria for educational events sponsored by Novo Nordisk, Inova Pharmaceuticals, and Johnson & Johnson and for serving on advisory boards for Novo Nordisk and Inova Pharmaceuticals. MS received financial support from the above grant (P00026163) as a project officer.
References
-
- World Health Organization. Obesity and overweight. 2021 14 October 2021]; Available from: https://www.who.int/news-room/fact-sheets/detail/obesity-and-overweight.
-
- Atlantis E, et al. Comparing the predictive ability of the Edmonton Obesity Staging System with the body mass index for use of health services and pharmacotherapies in Australian adults: a nationally representative cross-sectional study. Clin Obes. 2020;10(4):e12368. doi: 10.1111/cob.12368. - DOI - PubMed
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
